Cannabidiolic acid

Cannabidiolic Acid (CBDA): A Comprehensive Reference

1. Identity: Chemical and Botanical Characterization

Names and Nomenclature

Cannabidiolic acid (commonly abbreviated CBDA or CBDa) is a terpenophenolic phytocannabinoid found in Cannabis sativa L. Its systematic chemical name reflects the carboxylic acid (–COOH) functional group appended to the aromatic ring of the cannabidiol (CBD) skeleton. CBDA has the chemical formula C₂₂H₃₀O₄ and a molecular weight of 358.5 g/mol. By comparison, its neutral derivative CBD has the formula C₂₁H₃₀O₂ (MW 314.5), the difference arising from the carboxylic acid moiety lost during decarboxylation. CBDA is defined as the carboxylated form of CBD.

Botanical Source and Localization

CBDA is the main phytocannabinoid in fiber-type and seed-oil hemp (Cannabis sativa L.) plants. It is most abundant in the glandular trichomes on the female seedless flowers (infructescence), and is a natural product biosynthesized in cannabis via cannabidiolic acid synthase from the conjugation of olivetolic acid and cannabigerolic acid. CBDA synthase is the enzyme that catalyzes the oxidative cyclization of cannabigerolic acid into CBDA, making it the dominant cannabinoid constituent of fiber-type Cannabis sativa.

Discovery and Historical Elucidation

Isolated in 1955, CBDA was the first discovered cannabinoid acid. Its structure was elucidated in 1965 by analysis of the physical properties of its methyl ester (Mechoulam and Gaoni, 1965), and its synthesis from cannabidiol was subsequently reported (Mechoulam and Ben-Zvi, 1969). Despite this early discovery, research attention remained overwhelmingly focused on its neutral derivative CBD and the psychoactive cannabinoid THC, leaving CBDA a comparatively understudied compound for decades. Whereas cannabidiol has been the topic of a large number of publications and its biological/therapeutic properties have been reasonably well identified, knowledge of the pharmacology of cannabidiolic acid has remained much more limited.

Relationship to CBD: Biosynthesis and Decarboxylation

CBDA is the chemical precursor to cannabidiol (CBD). Through the process of decarboxylation, cannabidiol is derived through loss of the carbon and two oxygen atoms that make up the carboxylic acid moiety on the aromatic ring. CBDA gradually decarboxylates, while still in the plant, to cannabidiol, a process that is speeded up by heat. This means that any cannabis or hemp material subjected to smoking, vaporization, or cooking will convert most of its CBDA into CBD; CBDA is thus characteristic of fresh, raw, or minimally processed plant material.

A unique enzyme that catalyzes the oxidocyclization of cannabigerolic acid to CBDA in Cannabis sativa was identified and named CBDA synthase. Biochemical characterization demonstrated that CBDA synthase is a covalently flavinylated oxidase, and its structural and functional properties are quite similar to those of THCA synthase, which is responsible for the biosynthesis of THCA—the major cannabinoid in drug-type cannabis plants.

Common Forms and Preparations

CBDA is present in several commercially available product forms, each designed to preserve or exploit its acidic, non-decarboxylated form:

• Raw or "cold-process" hemp extracts and oils: Sometimes labeled as "raw CBD oil" or "full-spectrum raw extract," these preparations retain CBDA alongside other cannabinoid acids by avoiding heat during extraction and processing. CBDA is present in the fresh cannabis plant, particularly in its industrial hemp forms, and gradually undergoes decarboxylation into CBD, with heating or burning of the plant material accelerating this process.
• Fresh cannabis juice: Juicing raw cannabis leaves and flowers is one method to consume CBDA in unprocessed form, as no heat decarboxylation occurs.
• Magnesium-stabilized preparations: Magnesium ions have been used to stabilize CBDA-enriched hemp extracts (such as Mg-CBDA and Chylobinoid), which have been compared with CBD in anticonvulsant activity studies.
• CBDA methyl ester (HU-580 / CBDA-ME): A more stable methyl ester version of CBDA (CBDA-ME or HU-580) has demonstrated superior potency, suggesting it may also be a possible treatment option.
• Ethanol tinctures (cold-extracted): Traditional cannabis tinctures produced with cold ethanol can preserve significant amounts of CBDA, though traditional tinctures of Cannabis sativa L. became obsolete before elucidation of the main cannabinoids and routine quality testing for medicines.

2. Traditional and Historical Use

The documented traditional use of cannabis stretches back thousands of years; however, the specific contribution of CBDA within those traditions cannot be cleanly separated from that of cannabis as a whole. Since CBDA is the dominant cannabinoid in raw, unheated hemp and fresh cannabis, it would have been a major constituent of any preparation that did not involve burning or sustained heating.

Subsequent studies showed that cannabinoids are first formed as acids and decarboxylate upon drying or heating to form their neutral derivatives. This means that in historical preparations involving raw plant material—infusions in cold water, poultices of fresh leaves, or cold-solvent extracts—CBDA rather than CBD would have been the predominant compound present.

The specific compound CBDA as a chemically distinct entity was not known until 1955. Prior to the modern scientific era, traditional healers worked with whole-plant preparations without knowledge of individual cannabinoids. High-performance liquid chromatography with diode-array detection (HPLC/DAD) has been used in modern research to determine THC, THCA, CBN, CBD, CBDA, CBG, and CBGA in traditional cannabis tinctures, with profiles characterized across plant parts, extraction solvents, and storage conditions. Such analyses confirm that raw preparations naturally contain substantial CBDA.

The cultivation of industrial hemp varieties approved by the European Union, with limited THC content, has been augmenting interest in the acidic derivatives; CBDA, which represents the main compound in fiber-type and seed-oil plants, is becoming a true protagonist, but its beneficial outcomes are still hidden and unexplored.

3. Key Chemical Constituents and Mechanisms of Action

Structural Basis of Activity

Methylation of the carboxylic acid moiety of CBDA leads to disappearance of COX-2 selectivity. Thus, the carboxylic acid moiety in CBDA is a key determinant for its inhibitory action. This structural feature distinguishes CBDA from CBD and gives it a pharmacological profile that in several respects differs markedly from the neutral compound.

Cyclooxygenase-2 (COX-2) Inhibition

In vitro studies revealed that CBDA selectively inhibited cyclooxygenase (COX)-2 activity with an IC₅₀ value (50% inhibition concentration) around 2 μM, having 9-fold higher selectivity than COX-1 inhibition. In contrast, Δ⁹-tetrahydrocannabinolic acid (THCA) was a much less potent inhibitor of COX-2 (IC₅₀ >100 μM). The crude extract of cannabis containing mainly CBDA was shown to have a selective inhibitory effect on COX-2, suggesting that naturally occurring CBDA in cannabis is a selective inhibitor for COX-2. It should be noted, however, that other studies failed to replicate such results, and the COX-2 inhibitory mechanism remains under some scientific debate.

Serotonin 5-HT1A Receptor Enhancement

CBDA acts as an enhancer of serotonin 1A (5-HT1A) receptor activation, and also as an agonist of transient receptor potential cation channel vanilloid 1 (TRPV1) and other transient receptor potential channels. Compared with cannabidiol, CBDA displays significantly greater potency at inhibiting vomiting in shrews and nausea in rats, and at enhancing 5-HT1A receptor activation. The 5-HT1A receptor interaction is considered the primary mechanism underlying CBDA's anti-nausea, anxiolytic, and potential antidepressant effects.

PPARγ Activation and TRP Channel Modulation

Acidic cannabinoids including CBDA display unique pharmacological actions including cyclooxygenase-2 (COX-2) inhibition, peroxisome proliferator-activated receptor gamma (PPARγ) activation, transient receptor potential (TRP) channel modulation, and serotonin 5-HT1A receptor activity.

Anti-Cancer Cell Signaling

Results of investigation into CBDA's anti-cancer properties revealed that CBDA inhibits migration of the highly invasive MDA-MB-231 human breast cancer cells, apparently through a mechanism involving inhibition of cAMP-dependent protein kinase A, coupled with an activation of the small GTPase, RhoA. The chemical inhibition and down-regulation of cyclooxygenase-2 (COX-2), the expression of which has been detected in approximately 40% of human invasive breast cancers, are suggested to be involved in the CBDA-mediated abrogation of cell migration.

Anticonvulsant Mechanisms

CBDA enhances 5-HT1A receptor activation with significantly greater potency than CBD. By increasing potassium conductance, 5-HT1A receptor activation evokes neuronal membrane voltage hyperpolarization and has anticonvulsant effects in various experimental seizure models.

Independence from CB1 Cannabinoid Receptors

A notable pharmacological feature of CBDA is that many of its effects appear to be mediated independently of the canonical cannabinoid CB1 receptor. Findings support the hypothesis that CBDA can suppress signs of nausea and vomiting in a CB1 receptor-independent manner, raising the possibility that if used to ameliorate nausea or vomiting in the clinic, it would not trigger any CB1 receptor-mediated tolerability or abuse liability problems.

4. Scientific Evidence by Area of Use

4.1 Nausea and Vomiting

This is the area with the strongest and most consistent preclinical evidence for CBDA. Multiple independent animal studies have been conducted, and the compound has been characterized in detail in relation to its anti-emetic mechanism.

Preclinical (animal) evidence: CBDA at doses of 0.1 and/or 0.5 mg/kg (i.p.) potently interferes with motion-, LiCl-, and cisplatin-induced vomiting in the house musk shrew. CBDA also reduced acute nausea produced by LiCl, an effect that was prevented by pretreatment with the 5-HT1A receptor antagonist WAY100635, and not by rimonabant. The blockade by a 5-HT1A antagonist but not by a CB1 antagonist (rimonabant) confirms that the antiemetic mechanism is serotonergic rather than endocannabinoid in nature.

CBDA was 1000 times more potent than CBD in reducing acute nausea. Unlike THC, the antinausea effect of CBDA was mediated by agonism of 5-HT1A receptors, not CB1 receptors. Furthermore, subthreshold doses of CBDA potentiated the antinausea effect of the 5-HT3 receptor antagonist, ondansetron.

As well as reducing acute nausea, CBDA has the potential to reduce anticipatory (conditioned) nausea, an effect experienced by chemotherapy patients upon returning to the clinic in which they received their nauseating treatment. Anticipatory nausea is particularly clinically important because if post-treatment nausea and vomiting are not properly controlled, anticipatory nausea—a conditioned response to contextual cues associated with illness-inducing chemotherapy—can develop; once it develops, anticipatory nausea is refractive to current anti-emetics, highlighting the need for alternative treatment options.

Clinical (human) evidence: CBD has demonstrated efficacy in reducing nausea and vomiting, with CBDA and CBDA-ME being more potent; the data suggest a need for these compounds to be evaluated in clinical trials for their ability to reduce nausea and/or vomiting. As of the available literature, CBDA has not been evaluated in rigorous, controlled human clinical trials for nausea and vomiting. Evidence remains at the preclinical (animal model) stage. It is time to take some of the preclinical findings (in particular CBDA) into clinical trials for the treatment of acute and anticipatory nausea, according to reviewers in Frontiers in Pharmacology.

Evidence strength: Strong in preclinical animal models; no published human clinical trial data as of current literature.

4.2 Inflammation

In vitro and preclinical evidence: CBDA may have anti-inflammatory qualities because it has been found to inhibit the inflammatory enzyme COX-2 selectively. In a comparison of CBDA and CBD for anti-hyperalgesic effects: in a rodent study, equivalent amounts of CBD and CBDA were administered to test efficiency in reducing hyperalgesia; the low amount of CBD was not efficient in reducing this increased sensitivity to pain when exposed to normal stimuli, while the CBDA did reduce hyperalgesia at the same low amount.

However, the COX-2 inhibitory data has not been consistently reproduced across laboratories. In vitro studies pointing to CBDA as a possible selective inhibitor of the proinflammatory enzyme COX-2 exist, although other studies failed in replicating such results.

Evidence strength: Preliminary; evidence is primarily in vitro and in rodent models, with conflicting replication. No human clinical trial data.

4.3 Anxiety and Depression

Preclinical evidence: CBDA has been shown to produce anxiolytic-like effects under conditions of high stress at doses as low as 0.1 μg·kg⁻¹ (i.p.) in animals. These anxiolytic effects are consistent with CBDA's established property of enhancing 5-HT1A receptor activation, as this receptor subtype is implicated in the modulation of anxiety and depression. CBDA has been shown to exert some therapeutic effects including anti-inflammatory, anti-emetic, anxiolytic, and antidepressant effects, although some of them remain under debate.

CBDA acts on serotonin 5-HT1A receptors, potentially improving mood, neuroplasticity, and behavioral symptoms, while also inhibiting COX-2 to suppress prostaglandin-mediated neuroinflammation.

Evidence strength: Preliminary preclinical data only; the anxiolytic and antidepressant effects of CBDA in humans have not been evaluated in clinical trials.

4.4 Epilepsy and Seizure Suppression

Preclinical evidence: A study demonstrated that CBDA raises the threshold for inducing thermogenic seizures in the Scn1aRX/+ mouse model of Dravet syndrome. CBDA was anticonvulsant against hyperthermia-induced seizures; a significant increase in generalized tonic-clonic seizure (GTCS) temperature threshold was observed with 10 and 30 mg/kg CBDA. CBDA was anticonvulsant at 10 and 30 mg/kg, which is lower than the effective dose of CBD (100 mg/kg), suggesting CBDA may be more potent than CBD.

Using stabilized CBDA formulations: Magnesium ion-stabilized CBDA-enriched hemp extracts (Mg-CBDA and Chylobinoid) have been compared with CBD in the maximal electroshock seizure test (MES) in rats and showed anticonvulsant activity.

The effective anticonvulsant dose of CBDA observed in mice equates to approximately 50 and 150 mg doses, respectively, in a 60 kg human (FDA interspecies conversion).

Note on CBD vs. CBDA in clinical epilepsy: It is important to distinguish between the clinical evidence for CBD and CBDA here. FDA-approved Epidiolex is a purified CBD product (not CBDA). Preclinical studies suggest that CBDA possesses anticonvulsant properties without the intoxicating effects of THC, making it a promising candidate for long-term therapy in both pediatric and geriatric populations. There are no published human clinical trials specifically evaluating CBDA for epilepsy.

Evidence strength: Preclinical animal model data (Dravet syndrome mouse model) is promising; no human clinical trial data for CBDA specifically.

4.5 Cancer Cell Migration Inhibition

In vitro evidence: Few studies investigated whether CBDA itself is biologically active in cancer models; results revealed that CBDA inhibits migration of the highly invasive MDA-MB-231 human breast cancer cells, apparently through a mechanism involving inhibition of cAMP-dependent protein kinase A, coupled with an activation of the small GTPase, RhoA. It is established that activation of the RhoA signaling pathway leads to inhibition of the mobility of various cancer cells, including MDA-MB-231 cells; the data suggest that as an active component in the cannabis plant, CBDA offers potential therapeutic modality in the abrogation of cancer cell migration.

When the anticancer activity of CBDA was investigated on acute lymphocytic leukemia, promyelocytic leukemia cells, and human prostate carcinoma androgen receptor-positive cells, CBDA was found to be less active than CBD for all of these, until tested towards MDA-MB-231 cells, a highly aggressive triple-negative breast cancer.

Evidence strength: In vitro (cell culture) data only; no animal model or human clinical trial evidence for anti-cancer effects.

4.6 Neuroinflammation

CBDA has been shown to be able to exert some therapeutic effects including anti-inflammatory effects, and one study assessed the potential behavioral effects of CBDA as well as its modulation of neuroinflammatory markers in the prefrontal cortex (PFC). CBDA acts on serotonin 5-HT1A receptors, potentially improving mood, neuroplasticity, and behavioral symptoms such as apathy and aggression in Alzheimer's disease models, while also inhibiting COX-2 to suppress prostaglandin-mediated neuroinflammation.

Evidence strength: Early-stage preclinical work only; no human data.

5. Body Systems and Health Areas Associated with CBDA

• Gastrointestinal system: Anti-nausea and anti-emetic effects via 5-HT1A receptor enhancement; reduction of both acute and anticipatory nausea in animal models.
• Inflammatory pathways: Selective COX-2 inhibition (with caveats regarding replication); relevance to pain and inflammatory conditions at the preclinical level.
• Central nervous system: Anxiolytic and putative antidepressant effects in animal models via 5-HT1A; anticonvulsant effects in Dravet syndrome mouse model; potential modulation of neuroinflammation in the prefrontal cortex.
• Oncology (in vitro): Inhibition of breast cancer cell migration; COX-2 down-regulation in aggressive breast cancer cell lines.
• Endocannabinoid system: CB1-independent mechanism of action, distinguishing CBDA from THC and suggesting low abuse liability.

Preclinical studies suggest that CBDA possesses anti-inflammatory, anticonvulsant, neuroprotective, anti-nausea, and anti-cancer properties without the intoxicating effects of THC, making it a promising candidate for long-term therapy in both pediatric and geriatric populations.

6. Dosage Forms and Dosages Reported in Studies

Because CBDA has not yet been evaluated in formal human clinical trials, no therapeutic dosage has been established for humans. The doses below are as reported in cited preclinical research and pharmacokinetic modeling.

• Anti-nausea (animal models, intraperitoneal): CBDA at a dose as low as 1 μg·kg⁻¹ (i.p.) can induce potent 5-HT1A receptor-mediated anti-nausea effects as indicated by its ability to prevent both vomiting in Suncus murinus and acute nausea-induced behavior in rats by enhancing 5-HT1A receptor activation. CBDA at doses of 0.1 and/or 0.5 mg/kg (i.p.) potently interferes with motion-, LiCl-, and cisplatin-induced vomiting in the house musk shrew.
• Anxiolytic (animal models, intraperitoneal): Anxiolytic-like effects have been observed at doses as low as 0.1 μg·kg⁻¹ (i.p.) under conditions of high stress in animals.
• Anticonvulsant (mouse model of Dravet syndrome, i.p.): A significant increase in GTCS temperature threshold was observed with 10 and 30 mg/kg CBDA. These doses equate to approximately 50 and 150 mg, respectively, in a 60 kg human by FDA interspecies conversion.
• Anti-cancer cell migration (in vitro, cell culture): Transwell migration assays were performed with 5 μM, 10 μM, or 25 μM CBDA to determine MDA-MB-231 cell migration.

The instability of CBDA, especially when subjected to heat, weakens the case for developing it as a medicine at standard oral doses, and this has driven interest in the more stable analogue CBDA-ME (HU-580).

7. Pharmacokinetics and Bioavailability

Pharmacokinetic studies indicate that CBDA generally exhibits low oral bioavailability, short half-lives, and limited central nervous system penetration under standard formulation conditions, with brain-to-plasma ratios remaining low unless specialized delivery systems (e.g., surfactants, nanoemulsions) are employed.

An important discovery regarding CBDA's pharmacokinetics concerns its status as a substrate of the drug efflux transporter BCRP (breast cancer resistance protein / ABCG2). Plasma CBDA concentrations were 14-times higher following administration in a cannabis extract than when administered as a single molecule. In vitro transwell assays identified CBDA as a substrate of the drug efflux transporter breast cancer resistance protein (BCRP), and that cannabigerol and Δ⁹-tetrahydrocannabinol inhibited the BCRP-mediated transport of CBDA. Such a cannabinoid-cannabinoid interaction at BCRP transporters located in the intestine would inhibit efflux of CBDA, thus resulting in increased plasma concentrations. This finding suggests that whole-plant or full-spectrum cannabis extracts, via an "entourage effect" mechanism at BCRP, could dramatically enhance CBDA oral bioavailability compared to isolated CBDA.

Results suggest that cannabis extracts provide a natural vehicle to substantially enhance plasma CBDA concentrations, and that CBDA might have a more significant contribution to the pharmacological effects of orally administered cannabis extracts than previously thought.

8. Chemical Instability

A central challenge in CBDA research and product formulation is its inherent chemical instability. A major challenge is the chemical instability of CBDA—it readily undergoes decarboxylation into its neutral form (CBD) when exposed to heat, light, or prolonged storage, which can significantly alter pharmacological activity. This instability complicates dosing accuracy and standardization, particularly in botanical preparations, and makes it challenging to ensure that patients are receiving the intended acidic form.

Even at room temperature, decarboxylation proceeds over time; any CBDA-containing product stored for extended periods may contain less CBDA and more CBD than stated at manufacture. This is a critical quality and reproducibility issue for research and supplement use alike.

9. Safety Considerations and Drug Interactions

Non-Psychoactivity

CBDA possesses its properties without the intoxicating effects of THC. Its mechanism of action is primarily CB1 receptor-independent, and if used to ameliorate nausea or vomiting, it would not trigger any CB1 receptor-mediated tolerability or abuse liability problems.

Limited Direct Human Safety Data

Challenges such as chemical instability, limited bioavailability, and a scarcity of clinical trials currently restrict CBDA's integration into mainstream medicine, underscoring the need for further pharmacological, clinical, and formulation research. Because no formal Phase I or Phase II human clinical trials with CBDA as the primary investigational compound have been published, there is no systematic characterization of its adverse effect profile in humans.

Drug Interaction: BCRP Efflux Transporter

The identification of CBDA as a BCRP substrate has significant drug interaction implications. CBDA is a substrate of the drug efflux transporter breast cancer resistance protein (BCRP), and cannabigerol and Δ⁹-THC inhibit the BCRP-mediated transport of CBDA. BCRP is also a transporter for numerous pharmaceutical drugs, including certain antibiotics, antineoplastics, antiretrovirals, and cardiovascular agents. Co-administration of CBDA with other BCRP substrates or inhibitors may alter the plasma concentrations of those drugs, though this has not been systematically studied in humans.

Implications of Decarboxylation to CBD

Because CBDA decarboxylates to CBD, safety considerations established for CBD (including the potential for liver enzyme elevation at high doses, particularly in combination with valproate, and interaction with CYP450 enzymes) are relevant to preparations containing CBDA, as a portion of any CBDA consumed will convert to CBD in vivo or prior to consumption. Both CBDA and its neutral form CBD readily undergo decarboxylation into their neutral or further metabolized forms when exposed to heat, light, or prolonged storage.

Instability as a Safety Consideration

The chemical instability of CBDA means that the actual CBDA content of a product may differ from labeled amounts, introducing uncertainty about what is actually being consumed and at what dose. This instability complicates dosing accuracy and standardization, particularly in botanical preparations.

Overall Evidence Gap

Research on the potential health benefits of CBDA is limited and most studies are based on animal models; even though preliminary results are promising, more clinical studies in humans are required. CBDA is still earlier than CBD in the human-evidence timeline: there are strong mechanistic and preclinical findings, plus emerging human pharmacokinetic research, but not a deep bench of large clinical outcome trials.

References

• (−)-Cannabidiolic Acid, a Still Overlooked Bioactive Compound: An Introductory Review and Preliminary Research — PubMed / Molecules (MDPI), 2020
• (−)-Cannabidiolic Acid, a Still Overlooked Bioactive Compound: An Introductory Review and Preliminary Research — PMC Full Text
• Purification and characterization of cannabidiolic-acid synthase from Cannabis sativa L. — PubMed, 1996
• Cannabidiolic-acid synthase, the chemotype-determining enzyme in the fiber-type Cannabis sativa — PubMed, 2007
• Cannabidiolic acid — Wikipedia
• Cannabidiolic acid as a selective cyclooxygenase-2 inhibitory component in cannabis — PubMed, 2008
• Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation — PubMed, 2013
• Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats — PMC Full Text
• Cannabidiolic acid methyl ester, a stable synthetic analogue of cannabidiolic acid, can produce 5-HT1A receptor-mediated suppression of nausea and anxiety in rats — PMC, 2018
• Regulation of nausea and vomiting by cannabinoids and the endocannabinoid system — PMC, 2014
• Cannabinoid Regulation of Acute and Anticipatory Nausea — PMC, 2017
• Therapeutic Potential of Cannabidiol, Cannabidiolic Acid, and Cannabidiolic Acid Methyl Ester as Treatments for Nausea and Vomiting — PMC, 2021
• Cannabinoids As Potential Treatment for Chemotherapy-Induced Nausea and Vomiting — Frontiers in Pharmacology, 2016
• Cannabidiolic acid, a major cannabinoid in fiber-type cannabis, is an inhibitor of MDA-MB-231 breast cancer cell migration — PubMed, 2012
• Cannabidiolic acid, a major cannabinoid in fiber-type cannabis, is an inhibitor of MDA-MB-231 breast cancer cell migration — PMC Full Text
• Cannabidiolic acid-mediated selective down-regulation of c-fos in highly aggressive breast cancer MDA-MB-231 cells — PubMed, 2016
• Cannabidiolic acid exhibits entourage-like improvements of anticonvulsant activity in an acute rat model of seizures — PMC, 2021
• Pharmacokinetics of Phytocannabinoid Acids and Anticonvulsant Effect of Cannabidiolic Acid in a Mouse Model of Dravet Syndrome — Journal of Natural Products, 2019
• Cannabis constituents interact at the drug efflux pump BCRP to markedly increase plasma cannabidiolic acid concentrations — Scientific Reports, 2021
• Cannabis constituents interact at the drug efflux pump BCRP to markedly increase plasma cannabidiolic acid concentrations — PMC Full Text
• Therapeutic potential of acidic cannabinoids: an update — PMC, 2024
• Cannabidiolic Acid — ScienceDirect Topics Overview
• Behavioural and molecular effects of cannabidiolic acid in mice — ScienceDirect / Life Sciences, 2020
• Getting to Know CBDA — Realm of Caring Foundation
• CBDA: New and Existing Research — Realm of Caring Foundation